Fibrosis

Biomodels has developed a pre-clinical animal model of pulmonary fibrosis that closely recapitulates the clinical condition in patients. Pulmonary fibrosis is occurs when the tissue around the alveoli in the lung becomes scarred and thickened, and it becomes difficult for oxygen to diffuse into the blood stream resulting in symptoms of dyspnea, dry cough, fatigue, unexplained weight loss and aching muscles and joints. Pulmonary fibrosis may be caused by occupational and environmental factors such as silica dust and asbestos fibers, radiation therapy, medications such as certain chemotherapy drugs, heart medications, antibiotics, and medical conditions such as tuberculosis and pneumonia. Complications of pulmonary fibrosis may include pulmonary hypertension, ventricular heart failure, respiratory failure and lung cancer.
Pulmonary fibrosis cannot be reversed and no current treatment is able to completely stop the progression of the disease. Medications such as corticosteroid, sometimes in combination with immunosuppressants, may improve symptoms. Other treatments such as oxygen therapy and pulmonary rehabilitation can improve the quality of life for pulmonary fibrosis patients.